EP1238069A2 - Antisense oligonucleotiden für mglur1 - Google Patents

Antisense oligonucleotiden für mglur1

Info

Publication number
EP1238069A2
EP1238069A2 EP00945507A EP00945507A EP1238069A2 EP 1238069 A2 EP1238069 A2 EP 1238069A2 EP 00945507 A EP00945507 A EP 00945507A EP 00945507 A EP00945507 A EP 00945507A EP 1238069 A2 EP1238069 A2 EP 1238069A2
Authority
EP
European Patent Office
Prior art keywords
rats
oligonucleotide
mgluri
treated
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00945507A
Other languages
English (en)
French (fr)
Inventor
Marian E. Fundytus
Terence J. Coderre
S. Robin Cohen
James L. Henry
Anneli Vainio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
McGill University
Original Assignee
McGill University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by McGill University filed Critical McGill University
Publication of EP1238069A2 publication Critical patent/EP1238069A2/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C12N2310/3125—Methylphosphonates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3511—Conjugate intercalating or cleaving agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP00945507A 1999-07-15 2000-07-17 Antisense oligonucleotiden für mglur1 Withdrawn EP1238069A2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14400499P 1999-07-15 1999-07-15
US144004P 1999-07-15
PCT/CA2000/000824 WO2001005963A2 (en) 1999-07-15 2000-07-17 ANTISENSE OLIGONUCLEOTIDES FOR METABOTROPIC GLUTAMATE RECEPTOR TYPE 1 (mGluR1)

Publications (1)

Publication Number Publication Date
EP1238069A2 true EP1238069A2 (de) 2002-09-11

Family

ID=22506645

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00945507A Withdrawn EP1238069A2 (de) 1999-07-15 2000-07-17 Antisense oligonucleotiden für mglur1

Country Status (4)

Country Link
EP (1) EP1238069A2 (de)
AU (1) AU5959900A (de)
CA (1) CA2377937A1 (de)
WO (1) WO2001005963A2 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11359197B2 (en) 2018-01-12 2022-06-14 Bristol-Myers Squibb Company Antisense oligonucleotides targeting alpha-synuclein and uses thereof

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1395289T3 (da) * 2001-06-07 2011-03-28 Christine Dr Sang Behandling af neuropatisk smerte med en N-methyl-D-aspartat- (NMDA-)receptorantagonist
WO2005075987A2 (en) * 2004-01-28 2005-08-18 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human metabotropic glutamate receptor 1 (mglur1)
US7615618B2 (en) * 2004-06-30 2009-11-10 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising a non-phosphate backbone linkage
CA2670116C (en) 2006-11-22 2015-03-10 Seaside Therapeutics, Llc Methods of treating mental retardation, down's syndrome, fragile x syndrome and autism
WO2011109398A2 (en) 2010-03-02 2011-09-09 President And Fellows Of Harvard College Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
US20110294879A1 (en) 2010-05-28 2011-12-01 Xenoport, Inc. Method of treatment of fragile x syndrome, down's syndrome, autism and related disorders
US20120016021A1 (en) 2010-07-15 2012-01-19 Xenoport, Inc. Methods of treating fragile x syndrome, down's syndrome, autism and related disorders
WO2012054724A1 (en) 2010-10-21 2012-04-26 Massachusetts Institute Of Technology Methods of treating seizure disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0105963A3 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11359197B2 (en) 2018-01-12 2022-06-14 Bristol-Myers Squibb Company Antisense oligonucleotides targeting alpha-synuclein and uses thereof
US11447775B2 (en) 2018-01-12 2022-09-20 Bristol-Myers Squibb Company Antisense oligonucleotides targeting alpha-synuclein and uses thereof

Also Published As

Publication number Publication date
CA2377937A1 (en) 2001-01-25
AU5959900A (en) 2001-02-05
WO2001005963A2 (en) 2001-01-25
WO2001005963A3 (en) 2001-11-08

Similar Documents

Publication Publication Date Title
US11530410B2 (en) Methods for treating hypercholesterolemia
AU2017202862B2 (en) Modulation of factor 11 expression
JP6704439B2 (ja) ハンチンチン発現の修飾
US8921331B2 (en) Methods for slowing familial ALS disease progression
JP6538736B2 (ja) Ｇｃｇｒ発現のアンチセンス調整
AU2008323970B2 (en) Modulation of Factor 7 expression
US8084437B2 (en) Methods for treating hypercholesterolemia
US20030186920A1 (en) Antisense oligonucleotide directed toward mammalian vegf receptor genes and uses thereof
US20110237646A1 (en) Modulation of transthyretin expression for the treatment of cns related disorders
CA3005249A1 (en) Compositions and methods for treatment of kidney diseases
KR20190062511A (ko) 아포지방단백질 ｃｉｉｉ （ａｐｏｃｉｉｉ） 발현의 조정
KR20210008498A (ko) Fxi 발현을 감소시키기 위한 화합물 및 방법
EP1238069A2 (de) Antisense oligonucleotiden für mglur1
US20060194750A1 (en) Methods and materials for modulating trpc4
US20130028889A1 (en) Dosing regimens for treating and preventing ocular disorders using c-raf antisense
WO2002013799A2 (en) Oligonucleotides and other modulators of the nk-1 receptor pathway and therapeutic uses thereof
US20080119423A1 (en) Methods and Materials For Modulating p2x2
US20060246432A1 (en) Methods and materials for modulating task-3
KR20140014365A (ko) 인자 ｘｉ에 의한 염증 반응의 조정

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020208

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040201